Kala Pharmaceuticals Inc (KALA) - Total Assets
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) holds total assets worth $9.49 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See debt-free asset ratio of Kala Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Kala Pharmaceuticals Inc - Total Assets Trend (2013–2025)
This chart illustrates how Kala Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check how high is Kala Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Kala Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kala Pharmaceuticals Inc's total assets of $9.49 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Kala Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Kala Pharmaceuticals Inc (KALA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kala Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2025, an increase from 84.4% in 2013.
- Cash Position: Cash and equivalents constituted 79.6% of total assets in 2025, up from 75.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kala Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Kala Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Kala Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.81 | 1.99 | 6.59 |
| Quick Ratio | 3.81 | 1.99 | 6.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.00 Million | $22.74 Million | $145.64 Million |
Kala Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Kala Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.50 |
| Latest Market Cap to Assets Ratio | 7.07 |
| Asset Growth Rate (YoY) | -82.9% |
| Total Assets | $9.49 Million |
| Market Capitalization | $67.11 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kala Pharmaceuticals Inc's assets at a significant premium (7.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Kala Pharmaceuticals Inc's assets decreased by 82.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kala Pharmaceuticals Inc (2013–2025)
The table below shows the annual total assets of Kala Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.49 Million | -82.90% |
| 2024-12-31 | $55.48 Million | -0.83% |
| 2023-12-31 | $55.95 Million | -35.56% |
| 2022-12-31 | $86.82 Million | -37.73% |
| 2021-12-31 | $139.43 Million | -37.08% |
| 2020-12-31 | $221.61 Million | +43.60% |
| 2019-12-31 | $154.32 Million | -30.16% |
| 2018-12-31 | $220.97 Million | +90.27% |
| 2017-12-31 | $116.13 Million | +150.67% |
| 2016-12-31 | $46.33 Million | +448.40% |
| 2015-12-31 | $8.45 Million | -27.93% |
| 2014-12-31 | $11.72 Million | +65.75% |
| 2013-12-31 | $7.07 Million | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more